Literature DB >> 10869359

Negative regulation of the serine/threonine kinase B-Raf by Akt.

K L Guan1, C Figueroa, T R Brtva, T Zhu, J Taylor, T D Barber, A B Vojtek.   

Abstract

B-Raf contains multiple Akt consensus sites located within its amino-terminal regulatory domain. One site, Ser(364), is conserved with c-Raf but two additional sites, Ser(428) and Thr(439), are unique to B-Raf. We have investigated the role of both the conserved and unique phosphorylation sites in the regulation of B-Raf activity in vitro and in vivo. We show that phosphorylation of B-Raf by Akt occurs at multiple residues within its amino-terminal regulatory domain, at both the conserved and unique phosphorylation sites. The alteration of the serine residues within the Akt consensus sites to alanines results in a progressive increase in enzymatic activity in vitro and in vivo. Furthermore, expression of Akt inhibits epidermal growth factor-induced B-Raf activity and inhibition of Akt with LY294002 up-regulates B-Raf activity, suggesting that Akt negatively regulates B-Raf in vivo. Our results demonstrate that B-Raf activity can be negatively regulated by Akt through phosphorylation in the amino-terminal regulatory domain of B-Raf. This cross-talk between the B-Raf and Akt serine/threonine kinases is likely to play an important role in modulating the signaling specificity of the Ras/Raf pathway and in promoting biological outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869359     DOI: 10.1074/jbc.M004371200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  80 in total

1.  S338 phosphorylation of Raf-1 is independent of phosphatidylinositol 3-kinase and Pak3.

Authors:  A Chiloeches; C S Mason; R Marais
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

Review 2.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

3.  Role of phosphoinositide 3-kinase and endocytosis in nerve growth factor-induced extracellular signal-regulated kinase activation via Ras and Rap1.

Authors:  R D York; D C Molliver; S S Grewal; P E Stenberg; E W McCleskey; P J Stork
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

4.  Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice.

Authors:  Juyeon Park; Jimmy Zhang; Jianhua Qiu; Xiaoxia Zhu; Alexei Degterev; Eng H Lo; Michael J Whalen
Journal:  J Cereb Blood Flow Metab       Date:  2011-09-21       Impact factor: 6.200

Review 5.  Opioid receptor trafficking and signaling: what happens after opioid receptor activation?

Authors:  Jia-Ming Bian; Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2011-09-25       Impact factor: 5.046

Review 6.  Mechanistic principles of RAF kinase signaling.

Authors:  Christian M Udell; Thanashan Rajakulendran; Frank Sicheri; Marc Therrien
Journal:  Cell Mol Life Sci       Date:  2010-09-06       Impact factor: 9.261

7.  Positive and negative regulation of Raf kinase activity and function by phosphorylation.

Authors:  H Chong; J Lee; K L Guan
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

Review 8.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

9.  Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms.

Authors:  Isabelle Hmitou; Sabine Druillennec; Agathe Valluet; Carole Peyssonnaux; Alain Eychène
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

10.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.